Fetal bovine serum has become an important tool fueling the biopharmaceutical and cell research industries in the USA from stem cell research and CAR T cells to vaccines production and antibodies creation. With the acceleration of innovations in the biopharmaceutical industry in the USA, the demand for reliable and traceable FBS has increased significantly among universities, biotech firms, and contract research organizations.
The increasing demand for FBS has changed how research facilities and biopharma companies procure their cell culture supplements. The increasing use of specialty FBS such as stem cell grade, exosome depleted and dialyzed sera has paved the way for advanced treatment methods and research in the country. Statistics reveal that as much as 60% of the leading FBS manufacturers have implemented ISO and cGMP standards by September 2024.
The U.S. Fetal Bovine Serum Market was valued at approximately USD 647.43 million in 2025 and is projected to reach around USD 1,831.68 million by 2033, driven by the country's expansive academic and research infrastructure and early adoption of specialty, high-value FBS products. Globally, the Fetal Bovine Serum Market was valued at USD 2.12 billion in 2025 and is expected to reach USD 6.03 billion by 2033, expanding at a CAGR of 13.99% during the forecast period of 2026–2033.
Gain Actionable Intelligence on the Fetal Bovine Serum Market – Request a Sample Report
U.S. Fetal Bovine Serum Market Analysis
The U.S. leads the worldwide fetal bovine serum market due to its highly developed research infrastructure consisting of universities, research centers, and contract research organizations which require high-quality serum for their experiments with cell cultures, stem cells and for drug discovery. Such advanced research infrastructure makes the country the leader in terms of having the most developed and valuable FBS market.
The growing number of cell-based research has been recognized as one of the main drivers of FBS consumption in the American market. The growing popularity of stem cells research, CAR-T treatment, and regenerative medicine has increased the demand for FBS used for mammalian cell culture in scientific research and drug development. The growth rate of regenerative medicine and vaccine production FBS usage has reached approximately 12% year-over-year as of November 2024, due to research related to tissue engineering and stem cells based therapies.
American laboratories and pharmaceutical companies are among the first users of high-quality FBS products. The growing investments into CAR-T treatment and cell-based research have increased the demand for stem cells grade and exosome depleted serum. The global financing of stem cell research reached USD 14.8 billion as of October 2024.
Top 5 Leading Fetal Bovine Serum Companies
1. Thermo Fisher Scientific
The Thermo Fisher Scientific Company is the leading provider of fetal bovine serum in the whole world with the products ranging from economical to application specific products that include research and biopharmaceutical applications. The broad distribution network and stringent following of ISO and cGMP quality standards have helped the company become the leading company in the U.S. and worldwide fetal bovine serum market.
The company is expanding its capability to cater to the increasing demand from Americans. It announced in March 2025 that it will increase its FBS manufacturing capacity in North America with the addition of stem cell-grade serum to cater to the field of regenerative medicines and biopharmaceuticals research.
2. GE Healthcare Life Sciences
GE Healthcare Life Sciences provides excellent quality FBS and cell culture media for vaccine production, stem cell therapy, research, and regenerative medicine research throughout the US. This is due to GE's well-established global distribution channel and extensive partnerships with American research facilities, which consolidate its dominant position in the FBS market.
It has continued to develop its specialized product portfolio by introducing an exosome depleted FBS product in September 2024.
3. Lonza Group Ltd.
Lonza offers specialty FBS products of high performance suitable for biopharmaceutical manufacturing, stem cell research, and vaccine manufacturing for American research establishments and biopharmaceutical firms. The company’s focus on regulation, traceability, and customization makes it a preferred supplier within the U.S. research industry.
The company has been consistently improving its quality assurance through its products, with its latest announcement in January 2025 about improved traceability and ISO-certified FBS batches for vaccine manufacture and cell therapy application.
4. Sigma-Aldrich
Sigma-Aldrich is a reputable supplier of quality FBS that supplies laboratories and biotech companies in the United States with FBS products used for research purposes. Sigma-Aldrich has become a popular choice among U.S. companies engaged in cellular studies due to its diverse range of products and quality standards.
The efforts of the company in maintaining product consistency and compliance with regulations ensure its good reputation among American researchers who require reliable and high-quality FBS.
5. Corning Incorporated
Corning Inc. provides cell culture reagents to the American scientific research and biopharmaceutical industry, and offers fetal bovine serum for use in research laboratories and in academia. Corning’s extensive involvement in life science infrastructure means that it is a household name in American laboratories.
Corning’s commitment to innovation in life sciences serves to ensure that it continues to support the increased need for quality cell culture reagents in American biopharmaceutical research labs.
What the Future of the Fetal Bovine Serum Market Holds
The future of the FBS market will see the growth of specialty products like stem cell-grade, exosome depleted and dialyzed FBS which will enable highly advanced studies and treatment purposes. Investment by academic institutions and contract research organizations will make for an increasing demand of research-grade FBS in the country.
Adherence to ISO and cGMP manufacturing standards will further improve the quality and demand for these serums in the market, while growing number of premium and specialty FBS products in the U.S. will continue providing opportunities for suppliers. Increasing investments in CAR-T treatment, tissue engineering and regenerative medicine will increase demand for high value specialty FBS products.
Since North America already makes up for 40.60% of the global fetal bovine serum market revenue in 2025 due to the presence of established biotechnology and pharmaceutical industry along with strong academic and research infrastructure, the United States can be predicted to be the biggest market for fetal bovine serum until 2033 and beyond.
